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Abstract
Interventional pediatric cardiology is a specialty of pediatric cardiology that deals spe-
cifically with the catheter-based treatment of congenital heart diseases. Cardiac catheter-
ization involves the evaluation and manipulation of the heart and surrounding vessels 
through catheters place in peripheral vessels. In this chapter we begin by discussing the 
significant difference between adult and pediatric interventional cardiology. We will 
discuss basic hemodynamic measurements performed in cardiac catheterization and its 
application to congenital heart disease. Stent and balloon catheters are briefly discussed. 
Finally, specific catheter based interventional techniques, indications, and complications 
for various pediatric congenital heart disease is described.
Keywords: pediatric interventional cardiology, valvuloplasty, angioplasty, balloon 
catheter, stent
1. Introduction to cardiac catheterization in congenital heart disease
Cardiac catheterization in the pediatric population has similarities with catheterization in 
adults but very distinct differences. In adults, the primary pathology is isolated coronary 
atherosclerotic disease, which is exceedingly rare in pediatrics, and valvular disease. The 
indications, techniques, and interventions performed in pediatrics are different. There are a 
wide range of therapeutic procedures performed in the pediatric cardiac catheterization lab 
including device closure of septal defects, balloon angioplasty of stenotic lesions and valvu-
loplasty of stenotic valves, stenting for vascular stenosis, embolization and device closure of 
vessels, and even percutaneous pulmonary valve implantation. A complete assessment of the 
patient is important as well as evaluating and determining the best sedation, vascular access, 
and potential interventions.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
At its most basic, cardiac catheterization is the evaluation and manipulation of the heart and 
related vessels by catheters placed through peripheral vessels. Most commonly, access is now 
obtained by the femoral artery and vein using a modified Seldinger technique, which involves 
placing a sheath and catheter over a wire. Alternative sites include the carotid and jugular, 
axillary, radial, subclavian, transhepatic, and even umbilical vessels in neonates. Anytime a 
catheter, wire, or sheath sits in a blood vessel, primarily an artery, there is a risk of occlusion, 
thromboembolism, and stroke. To prevent this, heparin is routinely administered throughout 
a catheterization case. Knowledge of basic technique and case-specific complications will help 
the practitioner in the management of these patients.
2. Basic hemodynamics
Traditionally, cardiac catheterization was the primary tool in the diagnosis and evaluation 
of congenital heart disease. Before the emergence of echocardiograms, clinical suspicion of 
congenital heart disease required a cardiac catheterization for definitive diagnosis, possible 
intervention, and pre-surgical planning. Cardiac catheterization can provide information 
such as angiographic images by fluoroscopic imaging during contrast injection, pressure 
measurements, oxygen blood saturations, and estimations of cardiac output and pulmonary 
vascular resistance. Pressure measurements are taken by way of a fluid-filled pressure trans-
ducer attached to a catheter with end-holes that are passed through various vessels and struc-
tures in the heart (Figure 1). The transducer produces cardiac pressure waveforms that are 
interpreted by the interventionalist (Figure 2). This is especially important in the evaluation 
of stenosis, diastolic dysfunction, and pulmonary vascular resistance.
Figure 1. Various cardiac catheters. (A) A thermodilution catheter used to calculate cardiac output. (B) A Berman catheter 
with an inflatable balloon and side holes is a multiuse catheter. (C) A pigtail multiuse catheter. The multiple side holes 
allow for angiography of arterial vessels.
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In each chamber of the heart, blood can be aspirated through a catheter and a blood oxygen 
saturation measured. These data can then be used to estimate a patient’s cardiac output and 
ratio of pulmonary blood flow to systemic blood flow (Qp:Qs). In 1870, Adolph Fick described 
a method for calculating blood flow which was refined and is now known as the Fick Method 
[1]. Basically, he explained that the release of a substance (in this case, oxygen consumption) 
in an organ is the product of blood flow across that organ and the concentration difference 
of a substance (oxygen content difference) proximal and distal to the organ. In other words:
  Cardiac output =  Oxygen consumption  _____________________ Oxygen content difference (1)
Oxygen consumption is often estimated based on normal values in older children and adults. 
Oxygen content difference is primarily the product of the change in hemoglobin saturation 
and the oxygen carrying capacity of hemoglobin (1.36).
  Oxygen content difference = 1.36 × hemoglobin × difference in oxygen saturations (2)
Using this principle, one can estimate the blood flow through any organ by knowing the 
oxygen blood saturations proximal and distal to the organ and the hemoglobin concentration 
of blood. In this way, sampling blood in the systemic veins proximal to the heart and blood 
in the aorta, distal to the heart, can estimate cardiac output. Similarly, sampling blood in the 
pulmonary arteries and pulmonary veins can estimate pulmonary blood flow.
Figure 2. Normal intracardiac pressure tracings in a 10 year old patient. (A) A simultaneous pressure tracing of the right 
ventricle (red) and the femoral artery (green). (B) Pressure tracing of the left ventricle.
Cardiac Catheterization in Congenital Heart Disease
http://dx.doi.org/10.5772/intechopen.79981
27
Resistance calculations are then based on Ohm’s law of electromagnetism. Georg Ohm was a 
German born scientist who in 1827 described that the electric current through a conductor is 
directly proportional to the potential voltage difference divided by the resistance. Modified 
for body fluid dynamics and a quick variation, it simply states that:
  Resistance =  ∆ Pressure ______________Flow (3)
Ohm’s law is used to calculate the pulmonary vascular resistance (PVR). The change in pres-
sure across the lungs is estimated by the difference between the left atrial pressure and pul-
monary artery pressure in a normal heart. The pulmonary blood flow is estimated by the 
Fick principle. PVR is an important measure in the diagnosis and management of pulmonary 
hypertension and pre-surgical planning.
3. Basic interventions
The majority of pediatric cardiac catheterization interventions include balloons, stents, and 
various devices. The equipment and tools of an interventional cardiologist varies based on 
experience level and new technological innovations. Attached to a specialized balloon cath-
eter, an inflatable and deflectable balloon is essential in the treatment of stenosis and the 
deployment of stents. There are a variety of different types of balloons that range in size, 
shape, and compliance. These specialized balloon catheters have end holes to inflate balloons 
with contrast solution so they are easily visible on fluoroscopy. Using a specialized device 
known as a gauge, the balloons are inflated, deflated, and removed from the patient. This is 
useful in the treatment of vessel stenosis and valve dilation. Balloon interventions carry lesion 
specific risks described in the subsequent sections of this chapter.
The first intravascular stent use in children was first described in the late 1980s. Indications 
include those stenotic lesions that are unresponsive to balloon dilation or recur frequently. 
Additionally, covered stents are using in treating significant tears or aneurysms. Each stent has 
its own set of characteristics including their size, strength, and “shortening” ability (Figure 3). 
Stents are metal or plastic mesh tubes that are loaded over balloon catheters and expandable 
Figure 3. A and B are two different kinds of bare metal stents used in pediatrics. Notice the interconnected mesh wiring 
and “tube” like shape.
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inside a vessel. Covered stents have a surgical fabric-coating that creates a contained tube that 
is expandable similar to bare stents. Finally, there are a number of devices used to embolize 
or close vessels and treat septal defects that are described in the following respective sections.
4. Patent ductus arteriosus
4.1. Introduction
The ductus arteriosus is an embryological vessel that connects the systemic and pulmonary 
circulation and serves to bypass the neonatal lungs. The vessel connects the pulmonary artery 
to the aortic arch. The patent ductus arteriosus (PDA) is a persistence of the ductus arteriosus 
after birth. The PDA is useful in cyanotic congenital heart diseases and is kept open until sur-
gical palliation in many cases. This is described further in the chapter on cyanotic congenital 
heart disease. In the absence of a cyanotic heart lesion, the isolated PDA allows for a portion 
of oxygenated blood from the left side of the heart to flow back towards the lungs. Isolated 
PDA accounts for 10% of all congenital heart disease and is unlikely to close naturally in term 
infants [2]. Long term complications can include congestive heart failure, infective endocardi-
tis, and pulmonary hypertension.
The first closure of the PDA was done by Gross and Hubbard in 1939. The first transcatheter 
closure of the PDA was performed by Portsmann et al. in 1967 and since then, there have been 
many developments in the closure of the PDA. Until recently, transcatheter closure of the 
PDA was not performed in infants less than 5–10 kg, but is now performed in infants as small 
as 600 g in some centers. Further innovation and experience in this procedure will result in a 
non-invasive, effective alternative to surgical PDA ligation in nearly all patients.
4.2. Indications
In older patients, the indications for closure of the PDA are well defined. Patients who have 
signs of left ventricular overload due to the left to right shunting of the PDA should be evalu-
ated for cardiac catheterization closure. A long-standing PDA can lead to congestive left 
sided heart failure and Eisenmenger’s syndrome similar to a ventricular septal defect. The 
indications for closure in neonates is more controversial. There is currently inadequate data 
for or against the closure of the PDA in young infants [3], but a general consensus is that 
transcatheter closure of the PDA in symptomatic infants at 2–3 weeks of age is both safe 
and effective. Alternatives include surgical ligation and medical closure with a non-steroidal 
anti-inflammatory drug such as indomethacin or acetaminophen. However, pharmacological 
treatment of the PDA is effective primarily in premature infants, and has an effective closure 
rate of around 68% [4].
4.3. Catheterization
Although the procedure is sometimes performed under only echocardiographic guidance 
and occasionally in the neonatal intensive care unit, we recommend fluoroscopy guidance 
in the cardiac catheterization lab. Traditionally, both femoral venous and arterial access is 
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Figure 4. Echocardiographic images of a PDA closure in a 4 week old premature infant who could not be extubated due 
to pulmonary edema. (A) Two-dimensional (2D) image of the aorta and the PDA as marked. (B) Color Doppler of the 
aorta and PDA showing opposite flow in each vessel. There is left to right shunting in the PDA. (C and D) After closure 
with a device, the PDA is no longer visualized by 2D or color Doppler.
obtained. Arterial access is used as a guide for the distal end of the ductus. Recent tech-
nique innovation requires only femoral venous access and placement of an esophageal tem-
perature probe. The probe acts as a landmark for the distal end of the ductus. The ductus 
is engaged by traversing a catheter through the pulmonary artery, ductus, and into the 
descending aorta.
First, an angiogram is performed to obtain measurements and describe the morphology of the 
PDA. A PDA with a pulmonary end diameter of less than 2.5 mm can occasionally be closed 
by coil embolization. These are spring wire coils enmeshed with polyester fibers and deliv-
ered through a catheter. The coil occludes the vessel by creating a wire and fabric framework 
that clots. In most PDAs, an occlusion device is used. A guidewire is used as an anchor and 
an occlusion device is loaded through a catheter into the PDA. There are various devices used 
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for PDA closure including vascular plugs and two-disk duct occluders similar to atrial septal 
device occluders. The diameter of the device should be at least the measured diameter of the 
ductus. Ideally, the device is situated entirely in the ductus arteriosus with no protrusion in 
either the pulmonary artery or the aorta. Once the device is in position, echocardiography is 
used to verify no residual shunting, and no obstruction to either the descending aorta or the 
branch pulmonary arteries. Once this is verified, the device is deployed (Figures 4–6).
4.4. Complications
The major complications of the procedure acutely are obstruction of the aorta or branch pul-
monary arteries and embolization of the device. The rate of embolization ranges from 1 to 3% 
and is nearly always retrievable by catheterization without surgical intervention. Loss of distal 
pulses and vascular injury has been shown to occur in around 20% of premature infants who 
Figure 5. Angiographic images of a PDA closure in a 4 year old patient who presented with left atrial and left ventricular 
dilation. (A) Contrast injection of the PDA through a pigtail catheter located in the aorta through a retrograde arterial 
course. (B) Contrast injection angiogram after closure of the duct with visualization of the PDA device. There is no visible 
stenosis of the aorta.
Figure 6. Angiograms of a PDA closure in an 800 g 28 week gestation infant who was unable to wean from ventilatory 
support. There was no arterial access in this patient. (A) An angiogram performed shows a large PDA similar in 
morphology to most premature infant ducts. (B) After closure with a microvascular plug device, there is no residual 
flow through the duct and the left pulmonary artery is unobstructed.
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had arterial access [5]. Infants also suffer an entity known as post ligation cardiac syndrome. 
Six to twelve hours after ligation, these patients suffer a transient low cardiac output state 
occasionally requiring additional inotropic support. Reported rates are as high as 50% [6].
5. Atrial septal defect
5.1. Introduction
Atrial septal defects (ASD) are holes between the right and left atrium of the heart. Their pres-
ence is noted in nearly half of all congenital defects and is important for preserved cardiac 
output and adequate mixing in a variety of critical congenital heart disease as described in the 
section on atrial septostomy [7]. Ostium secundum defects are the result of an embryological 
defect in the septum primum. They are the most common type of ASD with nearly 75% fit-
ting their description. Other types of ASDs include sinus venosus, coronary sinus, or ostium 
primum defects. Isolated atrial septal defects are typically asymptomatic in infants as the 
shunting across them is insignificant in early life. Eventually, patients may become symptom-
atic with frequent respiratory infections, though most are diagnosed due to the presence of 
a persistent murmur heard by a primary care practitioner and subsequent echocardiogram. 
Right ventricular and atrial dilation may be present along with a classic fixed split S2 heart 
sound on auscultation [8].
The first successful surgical closure of an ASD was performed in 1949. It was not until 1972 
that the first transcatheter closure of ASDs were performed in animal studies [9]. The first 
human patient to undergo transcatheter device closure of an ASD was a 17 year old girl in 
1975 using a Rashkind foam-covered, six-ribbed device [10]. Since that time, there have been 
numerous occlusion device revisions and innovations. Since the early 2000s, overall results 
from transcatheter atrial septal defect device closure have achieved results comparable if not 
exceeded those of surgical closure [11].
5.2. Indications
As stated before, patients with atrial septal defects rarely have clinically relevant symptoms. 
Ostium secundum defects are the only type of ASD amenable to device closure. In general, 
atrial septal defects should be closed in patients with right cardiac chamber enlargement with 
or without symptoms, a paradoxical embolism, or exercise related cyanosis. Patients who 
have severe pulmonary arterial hypertension unresponsive to vasodilator therapy, intracar-
diac thrombus, or a contraindication to antiplatelet agents should not undergo transcatheter 
closure. Additionally, defects must measure 36 mm or less, have adequate rims, and be located 
a safe distance from adjacent structures. Those that do not meet these criteria should undergo 
evaluation for surgical closure.
5.3. Catheterization procedure
All patients should have standard catheterization precautions with general anesthesia, anti-
biotic prophylaxis, and anti-coagulation with heparin. In particular, patients undergoing this 
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procedure should be started on aspirin before the procedure or be bridged with heparin. 
A transesophageal echocardiogram (TEE) is typically done simultaneously with the cardiac 
catheterization to ensure good positioning of the device and no residual defect or obstruction 
of other valves. Femoral venous percutaneous access is preferred. Arterial access is optional 
in these cases.
Initially, associated abnormalities including pulmonary venous abnormalities or associated 
atrial septal defects should be evaluated by TEE. Pressure and flow measurements are first 
obtained using a Berman or multiuse catheter. The defect is then crossed by a catheter and a 
wire is positioned in the left upper pulmonary vein through the defect to serve as an anchor. 
As the septal defects often stretch and are not symmetrical, balloon sizing is regularly per-
formed. A balloon stretched and sized ASD is usually 30% larger than the measured TEE 
dimension prior to intervention. Balloon sizing also allows for temporary occlusion of the 
Figure 7. Device closure of an ASD in a 10 y/o asymptomatic patient found to have moderate right atrial and right 
ventricular dilation. (A) The right atrium is moderately dilated due to a large ostium secundum atrial defect. (B) Color 
flow demonstrated all left to right shunt (blue color flow in the image). (C) Color Doppler after deployment of a two disk 
Amplatzer septal occluder shows no residual left to right shunting and complete closure of the ASD.
Cardiac Catheterization in Congenital Heart Disease
http://dx.doi.org/10.5772/intechopen.79981
33
ASD to determine its hemodynamic effects on the heart and whether the patient will tolerate 
closure. Once this is done, a device is advanced through a sheath to the defect. Most popular 
devices consist of a two disk system [Gore Helex Septal Occluder (HSO) (W.L. Gore, Flagstaff, 
AZ) and Amplatzer septal occluder (ASO) (AGA Medical, Golden Valley, MN)]. The distal 
disk is deployed in the left atrium and pulled back until it is snug against the atrial septum. 
The proximal disk is then deployed and the device is released (Figures 7 and 8). Post proce-
dure repeat chest films and echocardiograms over the next 24 hours are important to verify 
secure device positioning [12].
5.4. Complications
Reported severe complications in one study was as high as 7%, which is less than that of 
surgical closure [13]. During deployment of an occlusion device, components rotate and then 
return to their inherent shape. Device embolization is an unlikely complication but serious 
complication that occurs in the first 24–48 hours of the procedure. Erosion of a device into the 
adjacent anterosuperior wall or aorta is 0.1% in the US [14]. Incidence of device-associated 
thrombus is 1.2% and primarily occurs within the first month of the procedure. For this rea-
son, patients are typically placed on a regimen of aspirin and clopidogrel for 3–6 months. 
Arrhythmias, primarily atrial fibrillation can occur with any manipulation and scarring of the 
atrium. The post-procedure incidence of atrial fibrillation is 6% [15]. Additionally, endocardi-
tis prophylaxis is recommended for 6 months after device closure [12].
6. Balloon atrial septostomy
6.1. Introduction and indication
Balloon atrial septostomy, otherwise known as the Rashkind intervention, was described 
nearly 50 years ago as a life-saving emergent procedure required in particular congenital 
heart disease. Rashkind first described a transvenous approach for an atrial septostomy 
Figure 8. Fluoroscopic images of different deployed ASD closure devices. (A) Amplatzer septal occluder post deployment 
along with its delivery sheath. ASD closures are typically done under transesophageal echocardiographic guidance. (B) 
Cardioform septal occluder.
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in patients with transposition of the great arteries in the early 1960s. The procedure itself 
involves either widening an existing restrictive atrial level communication (Figure 9), or per-
forating the septum to manufacture a communication. Although the procedure is emergent, 
it can be planned even before birth based on fetal echocardiography. The primary purpose of 
an atrial septostomy is to enhance atrial mixing, decompressing the left atrium in a left sided 
obstructive lesion, or augmenting cardiac output in a right sided obstructed lesion. Primary 
congenital heart diseases that may require a balloon atrial septostomy include single ventricle 
physiology such as hypoplastic left heart syndrome and tricuspid atresia, transposition of 
the great arteries without a ventricular septal defect, and total anomalous pulmonary venous 
return.
6.2. Catheter procedure
The procedure can be performed in either the intensive care unit or a cardiac catheterization 
laboratory, the latter being preferred. In some centers, the infants are delivered in the cardiac 
catheterization lab to avoid any desaturation and cerebral hypoxia from delay. Access may 
someones be possible through the neonatal umbilical vein. If there are venous duct tortuosi-
ties, access through a femoral venous approach is required. Transthoracic echocardiographic 
guidance is highly recommended. Newborns are too small for a transesophageal echocardio-
gram. The patient should be anticoagulated with heparin and receive antibiotic prophylaxis 
at birth.
The procedure begins with advancing a balloon catheter into the right atrium and into the 
left atrium through the restrictive septum. In some cases, congenital heart disease such as 
hypoplastic left heart syndrome can have a thick atrial septum without any communica-
tion. In this case, a transseptal puncture needle or radiofrequency wire perforation may be 
required. Once the balloon is in the left atrium, it is inflated and, with a quick short move-
ment, is passed back to the right atrium where it is deflated (Figure 10). This procedure is 
repeated several times and the presence of an atrial shunt is confirmed by echocardiography 
(Figure 11). In rare cases, a stent can be placed in the interatrial communication for a long-
lasting result [16].
Figure 9. Transthoracic echocardiogram of a term newborn infant with D-transposition of the great vessels and a 
restrictive atrial septum. (A) 2D image of the restrictive atrial septal defect with bowing of the atrial septum. (B) There is 
nearly absent color Doppler signal across the defect representing scarce blood flow across the defect.
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6.3. Complications
Balloon atrial septostomy is a life-saving emergent procedure with rare complications. 
Rupture of the balloon with embolization of the fragments can occur and require retrieval [17]. 
Traumatic complications including damage or rupture of the atrial appendage, mitral valve, 
or pulmonary veins can occur. Stroke has been reported, but recent studies have shown no 
increase odds of brain injury in patients who undergo a balloon atrial septostomy [18]. The 
most common complications include transient cardiac arrhythmias that require rapid treat-
ment but generally resolve [16].
7. Coarctation of the aorta
7.1. Introduction
Coarctation of the aorta involves narrowing of various segments of the aorta. This often results 
in pathologic obstruction of systemic blood flow. Coarctation is the fourth most common 
Figure 11. Post atrial septostomy echocardiogram of the same patient. (A) The atrial septal defect has now been dilated. 
(B) Color Doppler reveals unobstructed left to right shunting across the newly widened defect.
Figure 10. Fluoroscopy of a balloon atrial septostomy in the same patient. (A) The balloon is inflated while positioned in 
the left atrium with the catheter through the restrictive atrial septal defect. (B) In a swift motion, the inflated balloon is 
pulled back to the right atrium to dilate the atrial septal defect. This process is repeated a number of times.
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congenital heart defect. It comprises of 7% of all congenital heart disease and affects ~0.04% 
of live births. Males are twice as likely to have coarctation compared to girls [19]. The more 
severe the narrowing, the more symptomatic a child will be, and the earlier the problem will 
be noticed. In some cases, coarctation is noted in infancy. In others, however, it may not be 
noted until school-age or adolescence. Symptoms may include diminished blood pressures 
in the lower extremities, diminished pulses in the lower extremities, and signs of left sided 
heart failure including poor feeding, poor weight gain, and cool extremities. In severe cases of 
coarctation of the aorta, babies may present with hypoxia [20].
Initially, transcatheter balloon angioplasty was introduced in the 1980s as an adjunctive treat-
ment to recurrent coarctation of the aorta following surgical therapy. Both treatments had 
flaws including re-coarctation of the aorta, residual hypertension, dissection of the aorta, 
and other aortic wall damage including aneurysm formation [21, 22]. To reduce complica-
tions and limitations, balloon-expandable stent therapy was introduced as a novel treatment 
for congenital heart diseases including coarctation of the aorta in the early 1990s [23]. Since 
that time, stent therapy has become widely accepted in children and adults for native and 
re-coarctation of the aorta [24].
7.2. Indications
The primary indication for repair in an older patient is an upper to lower-extremity systolic 
gradient of greater than 20 mmHg and/or the presence of symptoms including claudication 
and headaches. Of note, accurate blood pressure measurements are of the utmost importance. 
Ideally, three consecutive measurements in each extremity is required. Additional criteria 
include a diameter to diameter ratio of less than 0.6 between the narrowest portion of the 
coarctation of the abdominal aorta [25]. Cardiac balloon angioplasty and stent placement is 
rarely performed in small infants presenting with coarctation as rapid growth of the infant 
results in function coarctation from small stents.
7.3. Catheterization procedure
All patients should have standard catheterization precautions with general anesthesia, antibi-
otic prophylaxis, and anti-coagulation with heparin. The procedure occurs with a retrograde 
transfemoral approach by accessing both the femoral artery and vein. Care is taken to access 
the artery as proximal as possible and to avoid access past the bifurcation of the femoral 
artery. This ensures access to a large diameter vessel as larger stents require larger sheaths 
that can increase the risk of vascular compromise of the respective limb.
All patients undergo a complete right and left-heart catheterization as well as a detailed 
angiogram of the aorta using one of many various angiographic catheters such as a pigtail 
or multitrack catheter. Rotational angiography can provide additional imaging details of 
the aorta. Evaluating each branching vessel and its relationship to the coarctation segment is 
essential. Typically, a stiffer guidewire is positioned across the area of stenosis in preparation 
for stent placement.
Experience of the interventional cardiologist is of the utmost importance when choosing a 
stent. Typically, the diameter of the stent should not exceed the abdominal aorta diameter. 
Additionally, the ratio of the stent diameter to the narrowest coarctation segment should 
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be less than 3.5 [26]. Once the stent is chosen, it is loaded over a balloon-in-balloon cath-
eter. The inner balloon allows repositioning after partial deployment of the stent. Successful 
treatment is defined as a residual gradient less than 10 mmHg and post intervention ves-
sel caliber of greater than 80% of the normal adjacent aortic segment (Figure 12). Per the 
revised 2015 Bethesda guidelines, patients who have intravascular stent placement should 
avoid contact sports for 3–6 months post procedure. Patients often require continued anti-
hypertensive medications. They require antiplatelet therapy and endocarditis prophylaxis for 
up to 6 months post procedure [26].
7.4. Complications and stent/balloon angioplasty versus surgery
Outcomes are generally excellent in the acute and long-term setting. Persistent hypertension 
is noted in up to 23% of patients requiring continued anti-hypertensive medication. Aortic 
wall complications are rare but can be severe and lead to cardiovascular compromise. These 
include dissection and rupture. In a cohort of 565 procedures, there was a 1.6% rate of aortic 
wall pathology especially in patients who underwent pre-stent angioplasty, balloon angio-
plasty ratio > 3.5, and age greater than 40 years [27].
Aortic aneurysm is a complication in 5–9%. Most are small and do not require procedural 
re-intervention, but those that are progressive or large can be treated with placement of a 
covered stent [27, 28]. Cerebrovascular accidents are exceedingly rare with a rate of less than 
1% [29].
Various studies have compared outcomes between surgical repair, balloon angioplasty, and 
stent placement as treatments for coarctation of the aorta. A study by Forbes et al. compared 
Figure 12. Three-dimensional reconstruction of a rotational angiogram in an 8-year-old boy with severe coarctation of the 
aorta who underwent stent placement. (A) There is discrete stenosis at the aortic isthmus. A stent loaded balloon catheter 
can be seen across the narrow portion and into the ascending aorta. (B) Resolution of the angiographic coarctation with 
placement of a bare metal stent.
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intravascular stent placement, balloon angioplasty, and surgical repair in a cohort of 350 
patients and found that stent patients had fewer acute complications though at intermedia-
tion follow up there was no significant difference in persistent hypertension. There was a 
significantly higher ratio of the post intervention coarctation are to the adjacent descending 
aorta and a lower rate of aortic wall injury in the patients with intravascular stents compared 
to those with balloon angioplasty and surgical repair [25].
8. Aortic stenosis
8.1. Introduction
The aortic valve is a semilunar valve that connects the left ventricle to the aorta in the nor-
mal heart. The major difference between the aortic valve and pulmonary valve is the typical 
absence of an infundibular septum. Aortic stenosis occurs with obstruction below the valve 
(subvalvar), at the valve (valvar), and above the valve into the left ventricular outflow tract 
(supravalvar). Aortic stenosis accounts for 3–8% of all congenital heart disease. Valvar stenosis 
is the most common comprising of 75% of aortic stenosis. Of note, this is typically associated 
with either a bicuspid valve where two of the 3 cusps are fused, or a unicuspid valve where 
all three cusps are fused. Aortic stenosis is also associated with various other congenital heart 
defects as well as genetic syndrome such as Williams syndrome. Symptoms of aortic stenosis 
are similar to those of any left ventricular outflow tract obstruction including chest pain or syn-
cope with exercise and dyspnea on exertion. There may also be respiratory distress in infants 
caused by pulmonary edema, though this is typically absent in children and adults [30].
As with most other valvular disease, diagnosis is primarily made by an echocardiogram which 
is ordered based on clinical suspicion. Echocardiogram can demonstrate the morphology of 
the valve and characterize the location and degree of obstruction using both continuous wave 
and pulse wave Doppler, and color Doppler. Untreated aortic stenosis carries with it a 4% risk 
of endocarditis and a 5% risk of sudden death.
8.2. Indications
Aortic stenosis with less than a transvalvar gradient of 50 mmHg is typically well tolerated. 
Aortic stenosis is a progressive disease with between 21 and 41% of these patients progressing 
to severe aortic stenosis defined as a gradient of greater than 50 mmHg. There is an associated 
1% per patient-year risk of sudden death in these patients. Balloon aortic valvuloplasty is 
typically the first line treatment for patients with valvar aortic stenosis with a pressure gradi-
ent of greater than 50 mmHg and minimal aortic regurgitation. In patients with subvalvar and 
supravalvar stenosis, balloon angioplasty is typically not effective. Surgical repair by resec-
tion of the areas of stenosis is primarily the treatment for subvalvar and supravalvar stenosis.
8.3. Catheterization procedure
Most patients should have standard catheterization precautions with general anesthesia, anti-
biotic prophylaxis, and anti-coagulation with heparin. In some cases outside of the neonatal 
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period, the procedure can be performed under conscious sedation. The procedure occurs with 
a retrograde transfemoral approach by accessing both the femoral artery and vein. Care is 
taken to access the artery as proximal as possible and to avoid access past the bifurcation of 
the femoral artery.
This ensures access to a large diameter vessel as larger sheaths that can increase the risk of 
vascular compromise of the respective limb.
All patients undergo a complete right and left-heart catheterization as well as a detailed 
angiogram of the aorta and aortic valve. The most important measurement in a transvalvar 
gradient that can be obtained by a pullback measurement with a catheter, or simultaneous 
measurements in the aorta and left ventricle using either a trans-atrial-septal approach (in 
the presence of an ASD or PFO) or an additional arterial access point. The balloon size chosen 
should be 80–90% of the annulus size to reduce the risk of significant aortic regurgitation. 
Figure 13. Aortic balloon valvuloplasty in a 14 year old patient with moderate aortic valve stenosis and dizziness. (A) 
There is moderate stenosis at the level of the aortic valve. A pigtail catheter rests in the left ventricle retrograde from the 
aorta. (B) During balloon angioplasty of the valve, a “waist” is seen at the area of stenosis. (C) Post valvuloplasty there is 
no evidence of residual stenosis or aortic regurgitation.
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Once the procedure is complete, the gradient is remeasured. Typically, a successful angio-
plasty results in reducing the gradient by half without a significant increase in aortic regur-
gitation (Figure 13).
8.4. Complications
The most common complications with balloon aortic valvuloplasty are aortic regurgita-
tion and injury to the peripherally accessed vessel. Significant aortic regurgitation occurs in 
approximately 10% of all aortic valve balloon dilations which is comparable to rates in surgi-
cal valvotomy. Oversizing of the aortic balloon to be greater than the size of the aortic valve 
annulus is a primary risk factor. In patients with balloon ratios greater than 1.0 (I.E. a balloon 
larger than the diameter of the aortic valve annulus), at least moderate aortic regurgitation 
is seen in 25% of patients. Vascular injury is less common with improvement in techniques 
and availability of monitoring equipment [31]. Re-intervention is common and is reportedly 
required in up to 50% of patients. Typically, each subsequent intervention carries a higher 
risk of complications. The incidence of moderate aortic regurgitation in repeat dilations is at 
least 25% [32].
9. Pulmonary stenosis
9.1. Introduction
The pulmonary valve is a semilunar valve that connects the right ventricle to the pulmonary 
artery in a normal heart. Pulmonary stenosis is primarily a sequelae of congenital heart dis-
ease but can be acquired due to surgical or transcatheter interventions. Stenosis can occur 
at the level of pulmonary valve, above the pulmonary valve, or below the pulmonary valve. 
Valvular stenosis is the most common, accounting for up to 90% of cases [33]. It is often an 
isolated finding, but can be associated with congenital heart lesions, most notably tetral-
ogy of Fallot. It is also associated with genetic conditions such as DiGeorge syndrome and 
22q11 deletion, Williams syndrome, Alagille syndrome, congenital rubella, and Noonan’s 
syndrome. Noonan syndrome is particularly important as it results in dysplastic, thickened 
pulmonary valve leaflets that typically do not respond well to catheter-based balloon valvu-
loplasty. Patients with tetralogy of Fallot are more likely to have a component of sub-valvar 
and infundibular stenosis [34].
Patients with mild isolated pulmonary stenosis are typically asymptomatic and the stenosis 
rarely progresses rapidly. Symptoms are associated with the resulting decrease in cardiac 
output from stenosis. These include dyspnea on exertion, fatigue, and right ventricular hyper-
trophy, right ventricular diastolic and systolic dysfunction. Patients with severe pulmonary 
stenosis in the neonatal or early childhood can present with cyanosis in the setting of a intra-
cardiac shunt such as an atrial septal defect.
Diagnoses by echocardiogram is the gold standard. Two-dimensional and three-dimensional 
echocardiography can evaluate the morphology of the stenosis and pulmonary valve, and 
evaluate the function and size of the right ventricle. Continuous and pulse wave Doppler can 
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help determine pressure gradients and color Doppler can help quantify and resultant pulmo-
nary regurgitation. In some cases, MRI can accurately assess the degree of regurgitation, flow 
across the valve, and measure right ventricular size [35].
The three main treatment modalities for pulmonary valve stenosis are balloon pulmonary 
valvuloplasty, surgical valvotomy, and pulmonary valve replacement, either by surgery or 
cardiac catheterization. The first balloon valvuloplasty of the pulmonary valve was done in 
1979 and is by far the procedure of choice. Valvuloplasty is generally safe and effective in 
greater than 90% of patients [36].
9.2. Indications
Balloon pulmonary valvuloplasty is indicated for asymptomatic patients with a domed valve 
morphology, a peak gradient by echocardiography of greater than 60 mmHg, and up to 
moderate pulmonary regurgitation. Symptomatic patients are treated with an echocardio-
graphic gradient of greater than 50 mmHg and less than moderate pulmonary regurgitation. 
Immediate effects of balloon valvuloplasty include improved longitudinal right ventricular 
motion, reduced dyssynchrony in pediatric patients, reduction of tricuspid regurgitation, 
and improvement in the pulmonary valve gradient. Patients with supravalvar and subvalvar 
pulmonary stenosis may undergo balloon valvuloplasty but is often less effective, primarily 
in patients with Noonan syndrome.
9.3. Catheterization procedure
All patients should have standard catheterization precautions with general anesthesia, anti-
biotic prophylaxis, and anti-coagulation with heparin. Percutaneous femoral venous access 
is the preferred entry site for balloon pulmonary valvuloplasty. The procedure begins with 
pressure measurements of the right ventricular and pulmonary artery using a Berman or 
other multipurpose catheter. Pulmonary valve are can be calculated using the Gorlin formula. 
Simultaneous recording of the right ventricle and femoral artery pressure is done to assess 
severity of the obstruction. If the right ventricular systolic pressure is greater than 75% of the 
systemic systolic pressure, there is significant pulmonary valve obstruction. Angiography is 
an important tool in confirming the site of stenosis in addition to obtaining accurate measure-
ments of the pulmonary valve annulus [37].
A guidewire is positioned in the distal left pulmonary or right pulmonary artery. In infants, 
the wire may be positioned in the descending aorta through the patent ductus arteriosus. 
The purpose of the wire is to guide the balloon catheter and increase its stability. A number 
of different balloon catheters are available and are often chosen based on availability and 
experience of the interventional cardiologist. The diameter of the balloon should be 1.2–1.4 
times the size of the pulmonary valve annulus with a recommended ratio of 1.2–1.25 [38]. In 
cases of a dysplastic pulmonary valve, as is typically found in Noonan’s syndrome, a ratio of 
1.4–1.5 may be used [39]. Successful balloon valvuloplasty is defined as a residual gradient of 
less than 30 mmHg. Patients with successful valvuloplasty may return to competitive sports 
3–6 months post procedure (Figures 14 and 15).
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9.4. Complications
Severe complications are rare occurring in 0.6% of cases and mortality in 0.2% [40]. A major 
complication is transient but severe right ventricular outflow tract obstruction (sometimes 
Figure 14. Color Doppler transthoracic echocardiogram of a 2 year old patient with trisomy 21 and pulmonary stenosis 
who underwent balloon pulmonic valvuloplasty. (A) There is flow acceleration (blue and red color speckling) across 
the pulmonary valve indicating valvar stenosis. (B) Post balloon pulmonic valvuloplasty there is no flow acceleration or 
signs of obstruction.
Figure 15. Fluoroscopic images of the above patient during a balloon pulmonic valvuloplasty. (A) There is a thickened 
and stenotic pulmonary valve typical of patients with Noonan syndrome. (B) During balloon valvuloplasty a “waist” at 
the area of stenosis is seen.
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known as a “suicide right ventricle”) that can occur immediately after valvuloplasty. Long 
standing or severe pulmonary stenosis results in right ventricular hypertrophy. When the 
stenosis is resolved and the systolic right ventricular pressure drops, the hypertrophy results 
in acute narrowing of the outflow chamber and must be treated with fluid resuscitation and 
beta blockade [41].
The most common long term side effect is pulmonary regurgitation and recurrent pulmonary 
stenosis [42]. One study found that 60% of patients followed for 10 years after pulmonary 
valvuloplasty had at least moderate pulmonary regurgitation. However, pulmonary regurgi-
tation was well tolerated in the majority of patients. Only 5% had right ventricular dysfunc-
tion and 3% required intervention [43]. The lower the balloon:annulus ratio, the less risk of 
significant pulmonary regurgitation. The Long term impact of chronic pulmonary regurgi-
tation from pulmonary valvuloplasty is not well studied. Surrogate data from pulmonary 
regurgitation secondary to surgical valvotomy or valvectomy suggests that right ventricular 
function begins to deteriorate after the first several decades [44].
Restenosis occurs in up to 25% of patients who undergo valvuloplasty defined as a peak gra-
dient of >36 mmHg in 1–2 years post procedure. Around 15% of patients who have restenosis 
will require re-intervention with either surgery or repeat balloon pulmonary valvuloplasty. 
Risk factors for recurrent stenosis include a dysplastic valve, small annulus, high initial gradi-
ent, and a small balloon:annulus ratio defined as less than 1.2 [45].
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